Treatment for Alopecia Areata

https://www.medscape.com/s/viewarticle/998852?form=fpf

Excerpt: “The open-label extension trials of deuruxolitinib for alopecia areata in adults show a persistent climb in response with the majority of patients achieving complete or near complete hair regrowth by 52 weeks, according to data presented at the annual congress of the European Academy of Dermatology and Venereology.”